FindTrial
Sign In

Precision diagnosis and standardized treatment for juvenile myelomonocytic leukemia

Precision diagnosis and standardized treatment for juvenile myelomonocytic leukemia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036781
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile myelomonocytic leukaemia

Interventions

high risk:HSCT,demethylation drugs with FLAG chemotherapy before HSCT, demethylation drugs after HSCT
intermediate risk:Demethylation drugs
low risk:Watch and wait

Sponsors

Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of JMML as defined by the 2016 WHO criteria; 2. Aged <=18 years; 3. Written informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe organ dysfunction not caused by the disease; 2. Combined with other tumors (such as solid tumors) or hematopoietic diseases; 3. Prior hematopoietic stem cell transplantation or other intravenous chemotherapy.

Design outcomes

Primary

MeasureTime frame
Complete remission rate;disease-free survival rate;—

Countries

China

Contacts

Public ContactChen Jing

Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine

chenjingscmc@hotmail.com+86 021-38626161-82030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026